MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US2016/06/30STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug2016/06/08STEM CELL THERAPEUTIC
MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease2016/05/03STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance2016/04/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases2016/03/10STEM CELL THERAPEUTIC
MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease2016/01/13STEM CELL THERAPEUTIC
Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums2015/11/19STEM CELL THERAPEUTIC
‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency2015/11/02STEM CELL THERAPEUTIC
Selected as a conducting company of ‘global high-tech biomedicine industry’2015/10/26STEM CELL THERAPEUTIC
MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’2015/10/07STEM CELL THERAPEUTIC
